Recent Advances in Cancer Immunology and Immunotherapy

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 478

Special Issue Editors


E-Mail Website
Guest Editor
Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan
Interests: oxidant stress; DNA damage and repair; microenvironment and tumorigenesis; nature products; inflammation and cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan
2. School of Medicine, Tzu-Chi University, Hualien, Taiwan
Interests: acute lung injury; airway disease; pulmonary rehabilitation

E-Mail Website
Guest Editor
Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan
Interests: integrated traditional Chinese and western medicine; acupuncture; pulmonary medicine; phytomedicine

E-Mail Website
Guest Editor
Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan
Interests: cancer biology; Chinese herbal medicine; microRNA; biomarker; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer immunotherapy has revolutionized the treatment of various cancers, but has also presented new challenges because of treatment-induced resistance mechanisms in tumors and changes to patients' innate and adaptive immune responses. Several studies have revealed that cancer cells communicate with the immune system dynamically. Dynamic interaction between the tumor and the immune system, and with the cancer-specific therapy, occurs with each immunotherapy. Understanding these interactions will lead to the development of novel combination therapies and innovative sequencing approaches. In this Special Issue, we welcome articles, reviews, and perspectives regarding clinical and translational cancer immunotherapy, including in vitro and in vivo studies about new immunotherapeutic approaches and tumor–immune cell interactions, acquired immunity resistance to immunotherapy, and immunotherapy biomarkers.

Dr. Chan-Yen Kuo
Dr. Chou-Chin Lan
Dr. Po-Chun Hsieh
Dr. Guan-Ting Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarker
  • cancers
  • cancer immunology
  • immunotherapies
  • immune cells
  • immunotherapy resistance
  • tumor immunology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop